Institut d'Investigació Sanitària Illes Balears (IdISBa) Research Group.

Evolution of the Pseudomonas aeruginosa aminoglycoside mutational resistome in vitro and in the cystic fibrosis setting.

López-Causapé C1, Rubio R2, Cabot G2, Oliver A2.

1 Servicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria de las Islas Baleares (IdISBa), Palma de Mallorca, Spain. carla.lopez@ssib.es.
2 Servicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria de las Islas Baleares (IdISBa), Palma de Mallorca, Spain.

Abstract

Inhaled administration of high doses of aminoglycosides is a key maintenance treatment of Pseudomonas aeruginosa chronic respiratory infections in cystic fibrosis (CF). We analyzed the dynamics and mechanisms of step-wise high-level tobramycin resistance development in vitro and compared the results with those of isogenic pairs of susceptible-resistant clinical isolates. Resistance development correlated with fusA1 mutations in vitro and in vivo pmrB mutations, conferring polymyxin resistance, were also frequently selected in vitro In contrast, mutational overexpression of MexXY, a hallmark of aminoglycoside resistance in CF, was not observed in in vitro evolution experiments.

Antimicrobial Agents and Chemotherapy 2018. doi: 10.1128/AAC.02583-17.

 

Link to Pubmed

Tagged as: , , ,

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

ARPBIG IdISBa

Dr. Bartolome Moyà

Instituto de Investigación Sanitaria Illes Balears

Gabriel Torrens

%d bloggers like this: